PALM CITY, FL--(Marketwire - January 20, 2009) - GelStat Corporation (PINKSHEETS: GSAC), a
consumer healthcare company focused on the development and marketing of
safe and effective over-the-counter (OTC) products, is pleased to update
shareholders on recent events.
To all of our valued shareholders and the investment community:
Since our last update to shareholders in October of 2008, the following
projects have been completed:
-- Officially Launched GelStat Sleep on January 12, 2009. The product is
currently available on our website at https://gelstat.com/BuySleepNow.asp
-- Completed financial statements from the last 10Q filed with the SEC
for the period ending September of 2005 through the end of the third
quarter of 2008. Investors can access these reports at
-- Filed a Form 15 with the U.S. Security and Exchange Commission (SEC)
to temporarily suspend the Company's reporting requirements, while also
affirming the Company's intention to complete and submit 10Ks for 2005,
2006, 2007 and 2008 as well as complete and submit 10Qs for the first,
second and third quarters of 2006, 2007 and 2008.
-- Re-submitted a complete "Application Form for the Registration of a
Pharmaceutical Product" with the Ministry of Health in Kuwait in
conjunction with our Middle Eastern distribution partner Icarus Medical
-- Initiated advertising tests that have yielded positive return on
Our primary objectives moving forward will be focused on the following
-- Testing a number of advertising methods to determine which efforts
result in the highest revenues per advertising dollar. These efforts
include, but are not limited to: pay-per-click Internet, 3 minute
infomercial, 30 second and 60 second commercials, opt-in email campaigns,
Internet affiliate programs through banner ads, and tradeshows, as well as
sales calls to healthcare professionals and local retail chains.
-- Driving revenue growth by implementing advertising campaigns based on
the results of the aforementioned tests.
-- Liquidating inventory to strengthen the Company's balance sheet.
In summary, we have made significant progress over the last few months and
we are very excited about the launch of GelStat Sleep. It is estimated
that 100 million people suffer from some form of sleeplessness and we have
received a large number of positive testimonials on our product.
Furthermore, having two products available for sale significantly expands
our customer base and leverages our advertising dollars dedicated to
With virtually all of the restructuring projects completed, we can fully
commit our resources to driving revenue growth for a prosperous 2009. We
appreciate the continued support from our shareholders and will give
further updates as we achieve progress on the goals outlined above.
Gerald N. Kieft
ABOUT GELSTAT CORPORATION
GelStat Corporation is dedicated to providing safe and effective
over-the-counter (OTC) treatments for relief from migraine headaches,
sleeplessness and arthritis using all natural ingredients. GelStat's first
product, GelStat™ Migraine, is sold through direct-to-consumer channels,
retail chain stores, independent retailers and pharmacies. The Company also
has a suite of additional, effective healthcare products that address large
consumer markets including GelStat™ Sleep and GelStat™ Arthritis. For
more information, visit www.gelstat.com.
Safe Harbor Statement Under the Private Securities Litigation Act of 1995
With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks
and uncertainties. The actual future results of GelStat could differ
significantly from those statements. Factors that could cause actual
results to differ materially include risks and uncertainties such as the
inability to finance the company's operations or expansion, inability to
hire and retain qualified personnel, changes in the general economic
climate, including rising interest rate and unanticipated events such as
terrorist activities. In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "expect,"
"plan," "anticipate," "believe," "estimate," "predict," "potential," or
"continue," the negative of such terms, or other comparable terminology.
These statements are only predictions. Although we believe that the
expectations reflected in the forward-looking statements are reasonable,
such statements should not be regarded as a representation by the Company,
or any other person, that such forward-looking statements will be achieved.
We undertake no duty to update any of the forward-looking statements,
whether as a result of new information, future events or otherwise. In
light of the foregoing, readers are cautioned not to place undue reliance
on such forward-looking statements. For further risk factors, please review
our SEC filings.